Autologous HER2 Directed TMR CAR-T
Solid Tumors (e.g., GI Cancers)
Phase 1Active
Key Facts
About Exuma Biotechnology
EXUMA Biotech, founded in 2015 and based in Coral Gables, Florida, is advancing a suite of proprietary technologies designed to revolutionize cell and gene therapy delivery. The company's core platforms include the rPOC SC for ex vivo chemotherapy-free CAR-T and the GCAR platform for in vivo, off-the-shelf, and rechargeable CAR-T therapies, supported by enabling technologies like CD3-Targeted LVV and FITNESS DRIVER. With a clinical-stage pipeline, seasoned leadership, and a focus on expanding the settings of care, EXUMA is positioning itself to address significant unmet needs in oncology and autoimmunity.
View full company profile